| Document |
Document Title |
|
WO/2024/015594A1 |
Provided herein are irradiated mouse models which recapitulate the effects of ionizing radiation-induced microglia activation, eye injury and retinal degeneration, as well as methods for producing such mouse models. These mouse models ar...
|
|
WO/2024/015729A1 |
Provided is a system for regulating expression of a gene of interest in a target cell, including a recombinant first RNA molecule with (i) a coding sequence for a translation-suppressor protein and (ii) a first microRNA (miR) recognition...
|
|
WO/2024/013209A1 |
Disclosed herein are PCSK9 inhibitors. Also disclosed herein are methods of using PCSK9 inhibitors to treat certain diseases and disorders.
|
|
WO/2024/014468A1 |
Provided is a new pharmaceutical composition for treating or preventing arteriosclerosis. The pharmaceutical composition contains, as an active ingredient, a FoxO1 inhibitor.
|
|
WO/2024/015416A1 |
The present disclosure relates to compounds that are derivatives of the compound, celastrol, of formula (I), wherein R is an amide group and pharmaceutical compositions that include these celastrol derivative compounds. The disclosure al...
|
|
WO/2024/007954A1 |
The present invention relates to the technical field of drug treatment targets, and relates to a use of FPR1 as a drug target in the preparation of a drug for atherosclerosis. After three subtype receptors of FPR are fully studied and co...
|
|
WO/2024/007684A1 |
Provided is use of a compound represented by formula I or a pharmaceutically acceptable salt thereof as an Nrf2 activator, wherein m is independently selected from an integer from 0 to 4, and R 1 and R 2 are independently selected from h...
|
|
WO/2024/010915A1 |
A theranostic nanocomplex comprising albumin, bismuth sulfide (Bi2S3), and superparamagnetic iron oxide (SPIO) within a single nanoplatform and its use for tracking a cell, imaging a cell, and/or treating a disease, condition, or disorde...
|
|
WO/2024/008788A1 |
The invention relates to the use of ebselen or one of the derivatives thereof to treat mitochondrial pathologies or dysfunctions, in particular associated with deficiencies in complex I.
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/011178A1 |
Embodiments of the present disclosure recite methods of treating many diseases, such as inflammatory diseases, cancers, cardiovascular diseases, diabetes and obesity or conditions within a patient in need of such treatment by administeri...
|
|
WO/2024/008083A1 |
A compound as a CDK7 kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, can be used as a cyclin-dependent kinase 7 (CDK7) inhibitor, and is used for treating or preventing proliferative diseases (su...
|
|
WO/2024/010379A1 |
The present invention relates to a pharmaceutical composition that contains sustained-release microspheres composed of semaglutide or a pharmacologically acceptable salt thereof, a bioavailability enhancer, and a biodegradable polymer an...
|
|
WO/2024/008766A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2024/009144A1 |
Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obice...
|
|
WO/2024/010629A1 |
Disclosed herein are compositions and methods for delivering cannabidiol to subject in need of thereof. The disclosed compositions comprising CBD oil, edible oil and carrier are orally delivered for the treatment of hypertension. Further...
|
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
|
WO/2024/008088A1 |
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...
|
|
WO/2024/003205A1 |
The present invention relates to a pharmaceutical composition comprising (i) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 14; and/or (ii) a compound promoting the expressio...
|
|
WO/2024/003131A1 |
The present invention relates to an agent that inhibits the expression or activity of the G Protein-Coupled Receptor 182 (GPR182) protein for use in the treatment or prevention of a pathological condition selected from myocardial infarct...
|
|
WO/2024/003377A1 |
The invention relates to a nutritional composition comprising a combination of (i) co-enzyme Q10 with (ii) vitamin D and (iii) vitamin B2, for use in the treatment of stroke, preferably ischemic stroke. The invention also relates to a co...
|
|
WO/2024/003338A1 |
The present disclosure relates to a liquid pharmaceutical composition comprising an Annexin A1 (AnxA1) N-terminal-peptide and at least one pharmaceutically acceptable excipient for intravenous (i.v.) infusion and its use in the treatment...
|
|
WO/2024/003128A1 |
The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants the...
|
|
WO/2024/003904A1 |
The present invention is directed to combination therapies using compositions of Curcumin and Qing-Dai or extracts of plants producing thereof, and their clinical applications to the treatment of inflammatory conditions in general and to...
|
|
WO/2024/003535A2 |
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...
|
|
WO/2024/005211A1 |
Provided is a human Ad 5 vector etc., capable of avoiding immune response by existing antibody. The present invention is based on human adenovirus type 5 and pertains to a hexon-modified adenovirus vector in which the amino acid sequence...
|
|
WO/2024/002076A1 |
The present invention belongs to the technical field of recombinant adeno-associated virus (rAAV) gene therapy, relates to the preparation of an rAAV-delivered Fc-engineered VEGF receptor fusion protein or an anti-VEGF antibody, and is a...
|
|
WO/2024/002059A1 |
Provided is a method for treating a Parkinson's Disease, comprising a TRIM72 protein modulator. Further provided is a composition comprising the TRIM72 protein modulator and use thereof.
|
|
WO/2024/001964A1 |
Provided are a nimodipine composition free of ethanol and phospholipid for moist heat sterilization and a method for preparing same. The composition comprises: (1) nimodipine; (2) a non-phospholipid surfactant selected from a mixture of ...
|
|
WO/2024/006305A1 |
The present disclosure relates generally to compositions of nitroglycerin and related organic nitrates, and methods for treating conditions such as Raynaud's phenomenon in which peripheral blood flow in a subject is compromised.
|
|
WO/2024/005157A1 |
The purpose of the present invention is to provide: a novel adipocyte activator; and a use thereof. The present invention provides an adipocyte activator containing SerpinA1, a SerpinA1 expression promoter, or a SerpinA1 agonist, wherein...
|
|
WO/2024/004647A1 |
The purpose of the present invention is to provide heterotrophic microalgae having a high content of γ-aminobutyric acid, and a method for increasing the content of γ-aminobutyric acid in the heterotrophic microalgae. The present inv...
|
|
WO/2024/002056A1 |
Provided is a recombinant adeno-associated virus (rAAV) expression vector, comprising a gene encoding a TRIM72 protein or its variant or functional fragment thereof, wherein said recombinant AAV expression vector comprises a neuron-speci...
|
|
WO/2024/004656A1 |
Provided is a pharmaceutical composition that is a composition for treating an immune-related adverse event (irAE) in a subject who has undergone a cancer immunotherapy, the pharmaceutical composition containing anthracycline.
|
|
WO/2024/003560A1 |
The present invention provides a novel composition comprising Ashwagandha root (Witbania somnifera), Turmeric root (Curcuma longa), Lemon Balm Leaf (Melissa officinalis), Rhodiola Rosea root and Bilberry fruit (Vaccinium myrtillus). The ...
|
|
WO/2024/005124A1 |
The present invention relates to: a method for producing a non-human primate model of cerebral infarction, said method including administering an endothelin to the cerebral basal ganglia and thalamic area of a non-human primate and thus ...
|
|
WO/2024/005556A1 |
The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pha...
|
|
WO/2024/005197A1 |
Provided are: a solid dispersion comprising at least one compound selected from the group consisting of a hetero ring derivative represented by general formula [1], a tautomer of the hetero ring derivative, and a pharmaceutically accepta...
|
|
WO/2024/002062A1 |
Provided is a TRIM72 truncated protein, comprising the Coiled-PRYSPRY domain or PRYSPRY domain or its functional fragment of a TRIM72 protein. Further provided is the use of the TRIM72 truncated protein.
|
|
WO/2023/247312A1 |
Transthyretin amyloidosis is characterized by progressive deposition of the plasma protein transthyretin in the myocardium, peripheral nerves and/or other tissues, which can ultimately lead to congestive heart failure, polyneuropathy and...
|
|
WO/2023/248845A1 |
The present invention provides: a novel PTX3 expression control agent that uses miRNA from fine particles to control PTX3 expression, the PTX3 expression control agent including fine particles that include miRNA that targets a gene relat...
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/248844A1 |
Provided are: an HMGB1 expression suppressor comprising a microparticle, in which the microparticle contains miRNA of which the target gene is a gene associated with the expression of HMGB1, the HMGB1 expression suppressor being a novel ...
|
|
WO/2023/247596A1 |
The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2023/247595A1 |
The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2023/250024A1 |
This invention is directed to citrulline therapy, where citrulline is administered to achieve a newly recognized therapeutic window. The results of a completed clinical trial has elucidated a therapeutic window for L-citrulline. Detailed...
|
|
WO/2023/250140A1 |
Disclosed is a method for treating subarachnoid hemorrhage (SAH) and/or reducing the incidence of subsequent cerebral vasospasm in a patient. The method involves administering a therapeutically effective amount of a first compound or a p...
|
|
WO/2023/246355A1 |
Provided is a ginkgo leaf organic acid extract, which comprises the following components in percentage by weight: 60%-68% of protocatechuic acid, 10%-14% of 6-hydroxykynurenic acid, 5%-8% of gallic acid, 3%-8% of p-hydroxybenzoic acid wi...
|
|
WO/2023/247592A1 |
The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H- imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. p...
|
|
WO/2023/249965A1 |
The present application relates to compounds of Formula (I), Formula (II), and Formula (III) and to pharmaceutically acceptable salts and solvates of any of the foregoing, as well as pharmaceutical compositions and methods of using same ...
|
